Magnetic resonance studies of intramuscular interferon β-1a for relapsing multiple sclerosis

Annals of Neurology

Volumn 43, Issue 1, 1998, Pages 79-87

  Simon, Jack H ^a   Jacobs, Lawrence D ^b   Campion, Marilyn ^l   Wende, Karl ^c   Simonian, Nancy ^l   Cookfair, Diane L ^c   Rudick, Richard A ^d   Herndon, Robert M ^e,f   Richert, John R ^h   Salazar, Andres M ⁱ   Alam, John J ^l   Fischer, Jill S ^d   Goodkin, Donald E ^j   Granger, Carl V ^k   Lajaunie, Michelle ^a   Martens Davidson, Anna L ^c   Meyer, MaryJoel ^a   Sheeder, Jeanelle ^a   Choi, Kim ^a   Scherzinger, Ann L ^a   Bartoszak, David M ⁱ   Bourdette, Dennis N ^g   Braiman, Jonathan ⁱ   Brownscheidle, Carol M ^b   Coats, Michael E ⁱ   Cohan, Stanley L ^h   Dougherty, David S ⁱ   Kinkel, Revere P ^d   Mass, Michele K ^g   Munschauer III, Frederick E ^b   Priore, Roger L ^c   Pullicino, Patrick M ^b   Scherokman, Barbara J ^m   Weinstock Guttman, Bianca ^d   Whitham, Ruth H ^g   more..

^a UNIVERSITY OF COLORADO   (United States)

^b Millard Fillmore Gates Circle Hospital   (United States)

^c BUFFALO GENERAL HOSPITAL   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e Rheumatology Section   (United States)

^f Univ of Mississippi Medical Center   (United States)

^g OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^h GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

ⁱ WALTER REED ARMY MEDICAL CENTER   (United States)

^j UCSF Multiple Sclerosis Center   (United States)

^k UNIVERSITY AT BUFFALO   (United States)

^l BIOGEN   (United States)

^m KAISER PERMANENTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GADOLINIUM;

ARTICLE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NERVE LESION; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE;

BRAIN; DOUBLE-BLIND METHOD; GADOLINIUM; HUMANS; INJECTIONS, INTRAMUSCULAR; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; RECURRENCE; TREATMENT OUTCOME;

EID: 6844250787     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410430114     Document Type: Article

References (27)

1. Miller DH, Albert PS, Barkhof F, et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. Ann Neurol 1996;39:6-16
2. Simon JH. Magnetic resonance imaging of multiple sclerosis lesions: measuring outcome in treatment trials. West J Med 1996;164:502-509
3. Whitaker JN, McFarland HF, Rudge P, Reingold SC. Outcomes assessment in multiple sclerosis clinical trials: a critical analysis. Multiple Sclerosis 1995;1:37-47
4. Jacobs LD, Cookfair DL, Rudick RA, et al. A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis 1995;1:118-135
5. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-la for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294
6. Simon JH, Jacobs L, Cookfair D, et al. The Natural History of MS based on an annual MR snapshot: results from the MSCRG study of intramuscular recombinant interferon beta-1a. Neurology 1995;45(Suppl 4):A418
7. Paty DW, Li DKB, UBC MS/MRI Study Group, IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology 1993;43:662-667
8. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:1277-1285
9. Rudick RA, Goodkin DE, Jacobs LD, et al. The impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. Neurology 1997;49:358-363
10. Weinstock-Guttman B, Ransohoff RM, Kinkel RP, Rudick RA. The Interferons: biological effects, mechanisms of action, and use in multiple sclerosis. Ann Neurol 1995;37:7-14
11. Stone LA, Frank JA, Albert PS, et al. The effect of interferon-β on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol 1995;37:611-619
12. Pozzilli C, Bastianello S, Koudriavtseva T, et al. Magnetic resonance imaging changes with recombinant human interferon-β-1a: a short term study in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 1996;61:251-258
13. 2-weighted brain MRI activity in multiple sclerosis: a follow-up study. Neurology 1995;45:255-260
14. Stone LA, Albert PS, Smith ME, et al. Changes in the amount of diseased white matter over time in patients with relapsing-remitting multiple sclerosis. Neurology 1995;45:1808-1814
15. Simon JH, Scherzinger A, Raff, U, Li X. Computerized method of lesion volume quantitation in multiple sclerosis: errors of serial studies. AJNR 1997;18:580-582
16. Simon JH. Contrast-enhanced MR imaging in the evaluation of treatment response and prediction of outcome in multiple sclerosis. JMRI 1997;7:29-37
17. McFarland HF, Frank JA, Albert PS, et al. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 1992;32:758-766
18. Goodkin D, Rudick RR, VanderBrug Medendorp S. Low-dose oral methotrexate in chronic progressive multiple sclerosis: analysis of serial MRIs. Neurology 1996;47:1153-1157
19. Nauta JJP, Thompson AJ, Barkhof F, et al. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis patients: statistical power of parallel-groups and crossover designs. J Neurol Sci 1994;122:6-14
20. Barkhof F, Scheltens P, Frequin STFM, et al. Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity. AJR 1992; 159:1041-1047
21. Smith ME, Stone LA, Albert PS, et al. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions. Ann Neurol 1993;33:480-489
22. Kidd D, Thorpe JW, Thompson AJ, et al. Spinal cord MRI using multi-array coils and fast spin echo. Neurology 1993;42: 2632-2637
23. Hiehle JF, Grossman RI, Ramer KN, et al. Magnetization transfer effects in MR-detected multiple sclerosis lesions: comparison with gadolinium-enhanced spin-echo images and non-enhanced T1-weighted images. AJNR 1995;16:69-77
24. Gass A, Barker GJ, Kidd D, et al. Correlation of magnetization transfer ratio with clinical disability in multiple sclerosis. Ann Neurol 1994;36:62-67
25. DeStefano N, Matthews PM, Antel JP, et al. Chemical pathology of acute demyelinating lesions and its correlation with disability. Ann Neurol 1995;38:901-909
26. 1-weighted) spin-echo images. Neurology 1995;45:1684-1690
27. Losseff NA, Webb SL, O'Riordan JI, et al. Spinal cord atrophy and disability in multiple sclerosis: a new reproducible and sensitive MRI method with potential to monitor disease progression. Brain 1996;119:701-708